Login Register Cart 0
Review Article

抗细菌病原体布鲁氏菌小分子抑制剂

卷 31, 期 27, 2024

发表于: 28 September, 2023

页: [4267 - 4285] 页: 19

弟呕挨: 10.2174/0929867331666230915153910

价格: $65

摘要

布鲁氏菌病仍然是世界上主要的人畜共患疾病之一。作为布鲁氏菌病的病原体，它有许多途径逃避免疫系统的识别，使其能够在宿主体内复制和繁殖，对人类和动物造成重大伤害。布鲁氏菌的致病机制尚未阐明，这使得从致病机制鉴定药物靶点成为一个挑战。金属酶靶点和布鲁氏菌特有的一些蛋白质靶点可用于开发抗该疾病的抑制剂。由于布鲁氏菌对抗生素的耐药性，迫切需要开发特异性小分子抑制剂来治疗布鲁氏菌病。本文就布鲁氏菌小分子抑制剂的研究进展进行综述，以期对后续研究具有指导意义。

关键词: 布鲁氏菌病，布鲁氏菌，药物靶点，抑制剂，治疗，高通量筛选。

« Previous Next »
[1]
Boschiroli, M.L.; Foulongne, V.; O’Callaghan, D. Brucellosis: A worldwide zoonosis. Curr. Opin. Microbiol., 2001, 4(1), 58-64.
[http://dx.doi.org/10.1016/S1369-5274(00)00165-X] [PMID: 11173035]
[2]
Kirk, M.D.; Pires, S.M.; Black, R.E.; Caipo, M.; Crump, J.A.; Devleesschauwer, B.; Döpfer, D.; Fazil, A.; Fischer-Walker, C.L.; Hald, T.; Hall, A.J.; Keddy, K.H.; Lake, R.J.; Lanata, C.F.; Torgerson, P.R.; Havelaar, A.H.; Angulo, F.J. World Health Organization estimates of the global and regional disease burden of 22 foodborne bacterial, protozoal, and viral diseases, 2010: A data synthesis. PLoS Med., 2015, 12(12), e1001921.
[http://dx.doi.org/10.1371/journal.pmed.1001921] [PMID: 26633831]
[3]
Atluri, V.L.; Xavier, M.N.; de Jong, M.F.; den Hartigh, A.B.; Tsolis, R.M. Interactions of the human pathogenic Brucella species with their hosts. Annu. Rev. Microbiol., 2011, 65(1), 523-541.
[http://dx.doi.org/10.1146/annurev-micro-090110-102905] [PMID: 21939378]
[4]
Yu, D.; Hui, Y.; Zai, X.; Xu, J.; Liang, L.; Wang, B.; Yue, J.; Li, S. Comparative genomic analysis of Brucella abortus vaccine strain 104M reveals a set of candidate genes associated with its virulence attenuation. Virulence, 2015, 6(8), 745-754.
[http://dx.doi.org/10.1080/21505594.2015.1038015] [PMID: 26039674]
[5]
Jamil, T.; Melzer, F.; Saqib, M.; Shahzad, A.; Khan Kasi, K.; Hammad Hussain, M.; Rashid, I.; Tahir, U.; Khan, I.; Haleem Tayyab, M.; Ullah, S.; Mohsin, M.; Mansoor, M.K.; Schwarz, S.; Neubauer, H. Serological and molecular detection of bovine brucellosis at institutional livestock farms in Punjab, Pakistan. Int. J. Environ. Res. Public Health, 2020, 17(4), 1412.
[http://dx.doi.org/10.3390/ijerph17041412] [PMID: 32098207]
[6]
Hassan, H.; Salami, A.; Nehme, N.; Hakeem, R.; El Hage, J.; Awada, R. In prevalence and prevention of brucellosis in cattle in Lebanon. Vet. World, 2020, 13(2), 364-371.
[7]
Liu, Z.; Shen, T.; Wei, D.; Yu, Y.; Huang, D.; Guan, P. Analysis of the epidemiological, clinical characteristics, treatment and prognosis of human brucellosis during 2014–2018 in Huludao, China. Infect. Drug Resist., 2020, 13, 435-445.
[http://dx.doi.org/10.2147/IDR.S236326] [PMID: 32104015]
[8]
Njenga, M.K.; Ogolla, E.; Thumbi, S.M.; Ngere, I.; Omulo, S.; Muturi, M.; Marwanga, D.; Bitek, A.; Bett, B.; Widdowson, M.A.; Munyua, P.; Osoro, E.M. Comparison of knowledge, attitude, and practices of animal and human brucellosis between nomadic pastoralists and non-pastoralists in Kenya. BMC Public Health, 2020, 20(1), 269.
[http://dx.doi.org/10.1186/s12889-020-8362-0] [PMID: 32093689]
[9]
Khan, A.U.; Melzer, F.; El-Soally, S.A.G.E.; Elschner, M.C.; Mohamed, S.A.; Sayed Ahmed, M.A.; Roesler, U.; Neubauer, H.; El-Adawy, H. Serological and molecular identification of Brucella spp. in pigs from Cairo and Giza Governorates, Egypt. Pathogens, 2019, 8(4), 248.
[http://dx.doi.org/10.3390/pathogens8040248] [PMID: 31756893]
[10]
Ezama, A.; Gonzalez, J.P.; Majalija, S.; Bajunirwe, F. Assessing short evolution brucellosis in a highly Brucella endemic cattle keeping population of Western Uganda: a complementary use of Rose Bengal test and IgM rapid diagnostic test. BMC Public Health, 2018, 18(1), 315.
[http://dx.doi.org/10.1186/s12889-018-5228-9] [PMID: 29506522]
[11]
Zhang, X.W.; Ren, P.; Huang, T.L. Treatment of severe refractory thrombocytopenia in brucellosis with eltrombopag: A case report. Pediatr. Infect. Dis. J., 2022, 41(8), e332-e335.
[http://dx.doi.org/10.1097/INF.0000000000003555] [PMID: 35421043]
[12]
Perkins, S.D.; Smither, S.J.; Atkins, H.S. Towards a Brucella vaccine for humans. FEMS Microbiol. Rev., 2010, 34(3), 379-394.
[http://dx.doi.org/10.1111/j.1574-6976.2010.00211.x] [PMID: 20180858]
[13]
Głowacka, P.; Żakowska, D.; Naylor, K.; Niemcewicz, M.; Bielawska-Drózd, A. Brucella–virulence factors, pathogenesis and treatment. Pol. J. Microbiol., 2018, 67(2), 151-161.
[http://dx.doi.org/10.21307/pjm-2018-029] [PMID: 30015453]
[14]
Whatmore, A.M.; Perrett, L.L.; MacMillan, A.P. Characterisation of the genetic diversity of Brucella by multilocus sequencing. BMC Microbiol., 2007, 7(1), 34.
[http://dx.doi.org/10.1186/1471-2180-7-34] [PMID: 17448232]
[15]
Corbel, M. Brucellosis: An overview. Emerg. Infect. Dis., 1997, 3(2), 213-221.
[http://dx.doi.org/10.3201/eid0302.970219] [PMID: 9204307]
[16]
Hisham, Y.; Ashhab, Y. Identification of cross-protective potential antigens against pathogenic Brucella spp. through combining pan-genome analysis with reverse vaccinology. J. Immunol. Res., 2018.
[17]
Ewalt, D.R.; Payeur, J.B.; Martin, B.M.; Cummins, D.R.; Miller, W.G. Characteristics of a Brucella species from a bottlenose dolphin (Tursiops truncatus). J. Vet. Diagn. Invest., 1994, 6(4), 448-452.
[http://dx.doi.org/10.1177/104063879400600408] [PMID: 7858024]
[18]
Ross, H.; Foster, G.; Reid, R.; Jahans, K.; MacMillan, A. Brucella species infection in sea-mammals. Vet. Rec., 1994, 134(14), 359.
[http://dx.doi.org/10.1136/vr.134.14.359-b] [PMID: 8017020]
[19]
Martirosyan, A.; Moreno, E.; Gorvel, J.P. An evolutionary strategy for a stealthy intracellular Brucella pathogen. Immunol. Rev., 2011, 240(1), 211-234.
[http://dx.doi.org/10.1111/j.1600-065X.2010.00982.x] [PMID: 21349096]
[20]
Grilló, M.J.; Blasco, J.M.; Gorvel, J.P.; Moriyón, I.; Moreno, E. What have we learned from brucellosis in the mouse model? Vet. Res., 2012, 43(1), 29.
[http://dx.doi.org/10.1186/1297-9716-43-29] [PMID: 22500859]
[21]
Martirosyan, A.; Gorvel, J.P. Brucella evasion of adaptive immunity. Future Microbiol., 2013, 8(2), 147-154.
[http://dx.doi.org/10.2217/fmb.12.140] [PMID: 23374122]
[22]
Jansen, W.; Demars, A.; Nicaise, C.; Godfroid, J.; de Bolle, X.; Reboul, A.; Al Dahouk, S. Shedding of Brucella melitensis happens through milk macrophages in the murine model of infection. Sci. Rep., 2020, 10(1), 9421.
[http://dx.doi.org/10.1038/s41598-020-65760-0] [PMID: 32523093]
[23]
Ma, Z.; Li, R.; Hu, R.; Deng, X.; Xu, Y.; Zheng, W.; Yi, J.; Wang, Y.; Chen, C. Brucella abortus BspJ is a nucleomodulin that inhibits macrophage apoptosis and promotes intracellular survival of Brucella. Front. Microbiol., 2020, 11, 599205.
[http://dx.doi.org/10.3389/fmicb.2020.599205] [PMID: 33281799]
[24]
Hop, H.T.; Reyes, A.W.B.; Huy, T.X.N.; Arayan, L.T.; Min, W.; Lee, H.J.; Rhee, M.H.; Chang, H.H.; Kim, S. Activation of NF-kB-Mediated TNF-Induced antimicrobial immunity is required for the efficient Brucella abortus clearance in RAW 264.7 Cells. Front. Cell. Infect. Microbiol., 2017, 7, 437.
[http://dx.doi.org/10.3389/fcimb.2017.00437] [PMID: 29062811]
[25]
Boschiroli, M.L.; Ouahrani-Bettache, S.; Foulongne, V.; Michaux-Charachon, S.; Bourg, G.; Allardet-Servent, A.; Cazevieille, C.; Liautard, J.P.; Ramuz, M.; O’Callaghan, D. The Brucella suis virB operon is induced intracellularly in macrophages. Proc. Natl. Acad. Sci. USA, 2002, 99(3), 1544-1549.
[http://dx.doi.org/10.1073/pnas.032514299] [PMID: 11830669]
[26]
Celli, J.; de Chastellier, C.; Franchini, D.M.; Pizarro-Cerda, J.; Moreno, E.; Gorvel, J.P. Brucella evades macrophage killing via VirB-dependent sustained interactions with the endoplasmic reticulum. J. Exp. Med., 2003, 198(4), 545-556.
[http://dx.doi.org/10.1084/jem.20030088] [PMID: 12925673]
[27]
Starr, T.; Ng, T.W.; Wehrly, T.D.; Knodler, L.A.; Celli, J. Brucella intracellular replication requires trafficking through the late endosomal/lysosomal compartment. Traffic, 2008, 9(5), 678-694.
[http://dx.doi.org/10.1111/j.1600-0854.2008.00718.x] [PMID: 18266913]
[28]
Roux, C.M.; Rolán, H.G.; Santos, R.L.; Beremand, P.D.; Thomas, T.L.; Adams, L.G.; Tsolis, R.M. Brucella requires a functional Type IV secretion system to elicit innate immune responses in mice. Cell. Microbiol., 2007, 9(7), 1851-1869.
[http://dx.doi.org/10.1111/j.1462-5822.2007.00922.x] [PMID: 17441987]
[29]
Ahmed, W.; Zheng, K.; Liu, Z.F. Establishment of chronic infection: Brucella’s stealth strategy. Front. Cell. Infect. Microbiol., 2016, 6, 30.
[http://dx.doi.org/10.3389/fcimb.2016.00030] [PMID: 27014640]
[30]
Pappas, G.; Akritidis, N.; Tsianos, E. Effective treatments in the management of brucellosis. Expert Opin. Pharmacother., 2005, 6(2), 201-209.
[http://dx.doi.org/10.1517/14656566.6.2.201] [PMID: 15757417]
[31]
Leite, D.M.C.; Brochet, X.; Resch, G.; Que, Y.A.; Neves, A.; Peña-Reyes, C. Computational prediction of inter-species relationships through omics data analysis and machine learning. BMC Bioinformatics, 2018, 19(S14)(Suppl. 14), 420.
[http://dx.doi.org/10.1186/s12859-018-2388-7] [PMID: 30453987]
[32]
Spink, W.W. Current status of therapy of brucellosis in human beings. J. Am. Med. Assoc., 1960, 172(7), 697-698.
[http://dx.doi.org/10.1001/jama.1960.63020070004016] [PMID: 13833372]
[33]
Xie, Q.; Zhang, X.; Cui, W.; Pang, Y. Construction of a nomogram for identifying refractory Mycoplasma pneumoniae pneumonia among macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children. J. Inflamm. Res., 2022, 15, 6495-6504.
[http://dx.doi.org/10.2147/JIR.S387809] [PMID: 36474517]
[34]
Ocon, P.; Reguera, J.M.; Morata, P.; Juarez, C.; Alonso, A.; Colmenero, J.D. Phagocytic cell function in active brucellosis. Infect. Immun., 1994, 62(3), 910-914.
[http://dx.doi.org/10.1128/iai.62.3.910-914.1994] [PMID: 8112863]
[35]
Rizzo-Naudi, J.; Griscti-Soler, N.; Ganado, W. Human brucellosis: An evaluation of antibiotics in the treatment of brucellosis. Postgrad. Med. J., 1967, 43(502), 520-526.
[http://dx.doi.org/10.1136/pgmj.43.502.520] [PMID: 6074152]
[36]
Alizadeh, H.; Salouti, M.; Shapouri, R. Bactericidal effect of silver nanoparticles on intramacrophage Brucella abortus 544. Jundishapur J. Microbiol., 2014, 7(3), e9039.
[http://dx.doi.org/10.5812/jjm.9039] [PMID: 25147682]
[37]
Khan, A.U.; Shell, W.S.; Melzer, F.; Sayour, A.E.; Ramadan, E.S.; Elschner, M.C.; Moawad, A.A.; Roesler, U.; Neubauer, H.; El-Adawy, H. Identification, genotyping and antimicrobial susceptibility testing of Brucella spp. isolated from livestock in Egypt. Microorganisms, 2019, 7(12), 603.
[http://dx.doi.org/10.3390/microorganisms7120603] [PMID: 31766725]
[38]
Hashemi, S.H.; Gachkar, L.; Keramat, F.; Mamani, M.; Hajilooi, M.; Janbakhsh, A.; Majzoobi, M.M.; Mahjub, H. Comparison of doxycycline–streptomycin, doxycycline–rifampin, and ofloxacin–rifampin in the treatment of brucellosis: A randomized clinical trial. Int. J. Infect. Dis., 2012, 16(4), e247-e251.
[http://dx.doi.org/10.1016/j.ijid.2011.12.003] [PMID: 22296864]
[39]
Alavi, S.M.; Alavi, L. Treatment of brucellosis: A systematic review of studies in recent twenty years. Caspian J. Intern. Med., 2013, 4(2), 636-641.
[PMID: 24009951]
[40]
Johansen, T.B.; Scheffer, L.; Jensen, V.K.; Bohlin, J.; Feruglio, S.L. Whole-genome sequencing and antimicrobial resistance in Brucella melitensis from a Norwegian perspective. Sci. Rep., 2018, 8(1), 8538.
[http://dx.doi.org/10.1038/s41598-018-26906-3] [PMID: 29867163]
[41]
Majzoobi, M.M.; Hashmi, S.H.; Emami, K.; Soltanian, A.R. Combination of doxycycline, streptomycin and hydroxychloroquine for short-course treatment of brucellosis: A single-blind randomized clinical trial. Infection, 2022, 50(5), 1267-1271.
[http://dx.doi.org/10.1007/s15010-022-01806-x] [PMID: 35353333]
[42]
Peponis, V.; Kyttaris, V.C.; Chalkiadakis, S.E.; Bonovas, S.; Sitaras, N.M. Review: Ocular side effects of anti-rheumatic medications: What a rheumatologist should know. Lupus, 2010, 19(6), 675-682.
[http://dx.doi.org/10.1177/0961203309360539] [PMID: 20144965]
[43]
Shah, V.A.; Pandya, H.K.; Robinson, M.; Mandal, N. Hydroxychloroquine retinopathy: A review of imaging. Indian J. Ophthalmol., 2015, 63(7), 570-574.
[http://dx.doi.org/10.4103/0301-4738.167120] [PMID: 26458473]
[44]
del Pozo, J.S.G.; Solera, J. Treatment of human brucellosis-Review of evidence from clinical trials. In: Updates on Brucellosis; Baddour, M.M., Ed.; InTech, 2015. Available from:
[http://dx.doi.org/10.5772/59890.]
[45]
Hosseini, S.M.; Farmany, A.; Alikhani, M.Y.; Taheri, M.; Asl, S.S.; Alamian, S.; Arabestani, M.R. Co-Delivery of Doxycycline and hydroxychloroquine using CdTe-Labeled solid lipid nanoparticles for treatment of acute and chronic Brucellosis. Front Chem., 2022, 10, 890252.
[http://dx.doi.org/10.3389/fchem.2022.890252] [PMID: 35646816]
[46]
Zai, X.; Yin, Y.; Guo, F.; Yang, Q.; Li, R.; Li, Y.; Zhang, J.; Xu, J.; Chen, W. Screening of potential vaccine candidates against pathogenic Brucella spp. using compositive reverse vaccinology. Vet. Res., 2021, 52(1), 75.
[http://dx.doi.org/10.1186/s13567-021-00939-5] [PMID: 34078437]
[47]
Zhu, L.; Feng, Y.; Zhang, G.; Jiang, H.; Zhang, Z.; Wang, N.; Ding, J.; Suo, X. Brucella suis strain 2 vaccine is safe and protective against heterologous Brucella spp. infections. Vaccine, 2016, 34(3), 395-400.
[http://dx.doi.org/10.1016/j.vaccine.2015.09.116] [PMID: 26626213]
[48]
Chen, F.; He, Y. Caspase-2 mediated apoptotic and necrotic murine macrophage cell death induced by rough Brucella abortus. PLoS One, 2009, 4(8), e6830.
[http://dx.doi.org/10.1371/journal.pone.0006830] [PMID: 19714247]
[49]
Yang, X.; Skyberg, J.A.; Cao, L.; Clapp, B.; Thornburg, T.; Pascual, D.W. Progress in Brucella vaccine development. Front. Biol., 2013, 8(1), 60-77.
[http://dx.doi.org/10.1007/s11515-012-1196-0] [PMID: 23730309]
[50]
Wang, B. Drug design of zinc-enzyme inhibitors: Functional, structural, and disease applications; John Wiley & Sons, 2009.
[51]
Baglini, E.; Ravichandran, R.; Berrino, E.; Salerno, S.; Barresi, E.; Marini, A.M.; Viviano, M.; Castellano, S.; Da Settimo, F.; Supuran, C.T.; Cosconati, S.; Taliani, S. Tetrahydroquinazole-based secondary sulphonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IV, and IX, and computational studies. J. Enzyme Inhib. Med. Chem., 2021, 36(1), 1874-1883.
[http://dx.doi.org/10.1080/14756366.2021.1956913] [PMID: 34340614]
[52]
Winum, J.Y.; Köhler, S.; Supuran, C.T. Brucella carbonic anhydrases: New targets for designing anti-infective agents. Curr. Pharm. Des., 2010, 16(29), 3310-3316.
[http://dx.doi.org/10.2174/138161210793429850] [PMID: 20819063]
[53]
Joseph, P.; Turtaut, F.; Ouahrani-Bettache, S.; Montero, J.L.; Nishimori, I.; Minakuchi, T.; Vullo, D.; Scozzafava, A.; Köhler, S.; Winum, J.Y.; Supuran, C.T. Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis. J. Med. Chem., 2010, 53(5), 2277-2285.
[http://dx.doi.org/10.1021/jm901855h] [PMID: 20158185]
[54]
Lopez, M.; Köhler, S.; Winum, J.Y. Zinc metalloenzymes as new targets against the bacterial pathogen Brucella. J. Inorg. Biochem., 2012, 111, 138-145.
[http://dx.doi.org/10.1016/j.jinorgbio.2011.10.019] [PMID: 22196018]
[55]
Joseph, P.; Ouahrani-Bettache, S.; Montero, J.L.; Nishimori, I.; Minakuchi, T.; Vullo, D.; Scozzafava, A.; Winum, J.Y.; Köhler, S.; Supuran, C.T. A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth. Bioorg. Med. Chem., 2011, 19(3), 1172-1178.
[http://dx.doi.org/10.1016/j.bmc.2010.12.048] [PMID: 21251841]
[56]
Vullo, D.; Nishimori, I.; Scozzafava, A.; Köhler, S.; Winum, J.Y.; Supuran, C.T. Inhibition studies of a β-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides. Bioorg. Med. Chem. Lett., 2010, 20(7), 2178-2182.
[http://dx.doi.org/10.1016/j.bmcl.2010.02.042] [PMID: 20211561]
[57]
Riafrecha, L.E.; Vullo, D.; Supuran, C.T.; Colinas, P.A. C -glycosides incorporating the 6-methoxy-2-naphthyl moiety are selective inhibitors of fungal and bacterial carbonic anhydrases. J. Enzyme Inhib. Med. Chem., 2015, 30(5), 857-861.
[http://dx.doi.org/10.3109/14756366.2014.967233] [PMID: 25291009]
[58]
Ombouma, J.; Vullo, D.; Köhler, S.; Dumy, P.; Supuran, C.T.; Winum, J.Y. N-glycosyl-N-hydroxysulfamides as potent inhibitors of Brucella suis carbonic anhydrases. J. Enzyme Inhib. Med. Chem., 2015, 30(6), 1010-1012.
[http://dx.doi.org/10.3109/14756366.2014.986119] [PMID: 25792504]
[59]
Köhler, S.; Ouahrani-Bettache, S.; Winum, J.Y. Brucella suis carbonic anhydrases and their inhibitors: Towards alternative antibiotics? J. Enzyme Inhib. Med. Chem., 2017, 32(1), 683-687.
[http://dx.doi.org/10.1080/14756366.2017.1295451] [PMID: 28274160]
[60]
Maresca, A.; Scozzafava, A.; Köhler, S.; Winum, J.Y.; Supuran, C.T. Inhibition of beta-carbonic anhydrases from the bacterial pathogen Brucella suis with inorganic anions. J. Inorg. Biochem., 2012, 110, 36-39.
[http://dx.doi.org/10.1016/j.jinorgbio.2012.02.009] [PMID: 22459172]
[61]
Ceruso, M.; Carta, F.; Osman, S.M.; Alothman, Z.; Monti, S.M.; Supuran, C.T. Inhibition studies of bacterial, fungal and protozoan β-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties. Bioorg. Med. Chem., 2015, 23(15), 4181-4187.
[http://dx.doi.org/10.1016/j.bmc.2015.06.050] [PMID: 26145821]
[62]
Vullo, D.; Del Prete, S.; Di Fonzo, P.; Carginale, V.; Donald, W.; Supuran, C.; Capasso, C. Comparison of the sulfonamide inhibition profiles of the β- and γ-carbonic anhydrases from the pathogenic bacterium Burkholderia pseudomallei. Molecules, 2017, 22(3), 421.
[http://dx.doi.org/10.3390/molecules22030421] [PMID: 28272358]
[63]
Köhler, S.; Foulongne, V.; Ouahrani-Bettache, S.; Bourg, G.; Teyssier, J.; Ramuz, M.; Liautard, J.P. The analysis of the intramacrophagic virulome of Brucella suis deciphers the environment encountered by the pathogen inside the macrophage host cell. Proc. Natl. Acad. Sci., 2002, 99(24), 15711-15716.
[http://dx.doi.org/10.1073/pnas.232454299] [PMID: 12438693]
[64]
Abdo, M.R.; Joseph, P.; Boigegrain, R.A.; Liautard, J.P.; Montero, J.L.; Köhler, S.; Winum, J.Y. Brucella suis histidinol dehydrogenase: Synthesis and inhibition studies of a series of substituted benzylic ketones derived from histidine. Bioorg. Med. Chem., 2007, 15(13), 4427-4433.
[http://dx.doi.org/10.1016/j.bmc.2007.04.027] [PMID: 17481905]
[65]
D’ambrosio, K.; Lopez, M.; Dathan, N.A.; Ouahrani-Bettache, S.; Köhler, S.; Ascione, G.; Monti, S.M.; Winum, J.Y.; De Simone, G. Structural basis for the rational design of new anti-Brucella agents: The crystal structure of the C366S mutant of l-histidinol dehydrogenase from Brucella suis. Biochimie, 2014, 97, 114-120.
[http://dx.doi.org/10.1016/j.biochi.2013.09.028] [PMID: 24140957]
[66]
Monti, S.M.; De Simone, G.; D’Ambrosio, K.S.; De Simone, G.; Ambrosio, K. L-Histidinol dehydrogenase as a new target for old diseases. Curr. Top. Med. Chem., 2016, 16(21), 2369-2378.
[http://dx.doi.org/10.2174/1568026616666160413140000] [PMID: 27072690]
[67]
Abdo, M.R.; Joseph, P.; Mortier, J.; Turtaut, F.; Montero, J.L.; Masereel, B.; Köhler, S.; Winum, J.Y. Anti-virulence strategy against Brucella suis: Synthesis, biological evaluation and molecular modeling of selective histidinol dehydrogenase inhibitors. Org. Biomol. Chem., 2011, 9(10), 3681-3690.
[http://dx.doi.org/10.1039/c1ob05149k] [PMID: 21461427]
[68]
Turtaut, F.; Lopez, M.; Ouahrani-Bettache, S.; Köhler, S.; Winum, J.Y. Oxo- and thiooxo-imidazo[1,5-c]pyrimidine molecule library: Beyond their interest in inhibition of Brucella suis histidinol dehydrogenase, a powerful protection tool in the synthesis of histidine analogues. Bioorg. Med. Chem. Lett., 2014, 24(21), 5008-5010.
[http://dx.doi.org/10.1016/j.bmcl.2014.09.020] [PMID: 25278235]
[69]
Turtaut, F.; Ouahrani-Bettache, S.; Montero, J.L.; Köhler, S.; Winum, J.Y. Synthesis and biological evaluation of a new class of anti-Brucella compounds targeting histidinol dehydrogenase: α-O-arylketones and α-S-arylketones derived from histidine. MedChemComm, 2011, 2(10), 995-1000.
[http://dx.doi.org/10.1039/c1md00146a]
[70]
Abdo, M.R.; Joseph, P.; Boigegrain, R.A.; Montero, J.L.; Köhler, S.; Winum, J.Y. Brucella suis histidinol dehydrogenase: Synthesis and inhibition studies of substituted N-L-histidinylphenylsulfonyl hydrazide. J. Enzyme Inhib. Med. Chem., 2008, 23(3), 357-361.
[http://dx.doi.org/10.1080/14756360701617107] [PMID: 18569340]
[71]
Green, E.R.; Mecsas, J. Bacterial secretion systems: An overview. Microbiol. Spectr., 2016, 4(1), 4.1.13..
[http://dx.doi.org/10.1128/microbiolspec.VMBF-0012-2015] [PMID: 26999395]
[72]
Baron, C. VirB8: a conserved type IV secretion system assembly factor and drug target. Biochem. Cell Biol., 2006, 84(6), 890-899.
[http://dx.doi.org/10.1139/o06-148] [PMID: 17215876]
[73]
O’Callaghan, D.; Cazevieille, C.; Allardet-Servent, A.; Boschiroli, M.L.; Bourg, G.; Foulongne, V.; Frutos, P.; Kulakov, Y.; Ramuz, M. A homologue of the Agrobacterium tumefaciens VirB and Bordetella pertussis Ptl type IV secretion systems is essential for intracellular survival of Brucella suis. Mol. Microbiol., 1999, 33(6), 1210-1220.
[http://dx.doi.org/10.1046/j.1365-2958.1999.01569.x] [PMID: 10510235]
[74]
Sieira, R.; Comerci, D.J.; Sánchez, D.O.; Ugalde, R.A. A homologue of an operon required for DNA transfer in Agrobacterium is required in Brucella abortus for virulence and intracellular multiplication. J. Bacteriol., 2000, 182(17), 4849-4855.
[http://dx.doi.org/10.1128/JB.182.17.4849-4855.2000] [PMID: 10940027]
[75]
Ke, Y.; Wang, Y.; Li, W.; Chen, Z. Type IV secretion system of Brucella spp. and its effectors. Front. Cell. Infect. Microbiol., 2015, 5, 72.
[http://dx.doi.org/10.3389/fcimb.2015.00072] [PMID: 26528442]
[76]
Xiong, X.; Li, B.; Zhou, Z.; Gu, G.; Li, M.; Liu, J.; Jiao, H. The VirB system plays a crucial role in Brucella intracellular infection. Int. J. Mol. Sci., 2021, 22(24), 13637.
[http://dx.doi.org/10.3390/ijms222413637] [PMID: 34948430]
[77]
Fronzes, R.; Schäfer, E.; Wang, L.; Saibil, H.R.; Orlova, E.V.; Waksman, G. Structure of a type IV secretion system core complex. Science, 2009, 323(5911), 266-268.
[http://dx.doi.org/10.1126/science.1166101] [PMID: 19131631]
[78]
Sun, Y.H.; Rolán, H.G.; den Hartigh, A.B.; Sondervan, D.; Tsolis, R.M. Brucella abortus virB12 is expressed during infection but is not an essential component of the type IV secretion system. Infect. Immun., 2005, 73(9), 6048-6054.
[http://dx.doi.org/10.1128/IAI.73.9.6048-6054.2005] [PMID: 16113325]
[79]
Atmakuri, K.; Cascales, E.; Christie, P.J. Energetic components VirD4, VirB11 and VirB4 mediate early DNA transfer reactions required for bacterial type IV secretion. Mol. Microbiol., 2004, 54(5), 1199-1211.
[http://dx.doi.org/10.1111/j.1365-2958.2004.04345.x] [PMID: 15554962]
[80]
Paschos, A.; Patey, G.; Sivanesan, D.; Gao, C.; Bayliss, R.; Waksman, G.; O’Callaghan, D.; Baron, C. Dimerization and interactions of Brucella suis VirB8 with VirB4 and VirB10 are required for its biological activity. Proc. Natl. Acad. Sci. USA, 2006, 103(19), 7252-7257.
[http://dx.doi.org/10.1073/pnas.0600862103] [PMID: 16648257]
[81]
Terradot, L.; Bayliss, R.; Oomen, C.; Leonard, G.A.; Baron, C.; Waksman, G. Structures of two core subunits of the bacterial type IV secretion system, VirB8 from Brucella suis and ComB10 from Helicobacter pylori. Proc. Natl. Acad. Sci. USA, 2005, 102(12), 4596-4601.
[http://dx.doi.org/10.1073/pnas.0408927102] [PMID: 15764702]
[82]
Paschos, A.; den Hartigh, A.; Smith, M.A.; Atluri, V.L.; Sivanesan, D.; Tsolis, R.M.; Baron, C. An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation. Infect. Immun., 2011, 79(3), 1033-1043.
[http://dx.doi.org/10.1128/IAI.00993-10] [PMID: 21173315]
[83]
Smith, M.A.; Coinçon, M.; Paschos, A.; Jolicoeur, B.; Lavallée, P.; Sygusch, J.; Baron, C. Identification of the binding site of Brucella VirB8 interaction inhibitors. Chem. Biol., 2012, 19(8), 1041-1048.
[http://dx.doi.org/10.1016/j.chembiol.2012.07.007] [PMID: 22921071]
[84]
Sharifahmadian, M.; Arya, T.; Bessette, B.; Lecoq, L.; Ruediger, E.; Omichinski, J.G.; Baron, C. Monomer‐to‐dimer transition of Brucella suis type IV secretion system component VirB8 induces conformational changes. FEBS J., 2017, 284(8), 1218-1232.
[http://dx.doi.org/10.1111/febs.14049] [PMID: 28236662]
[85]
Woese, C.R.; Olsen, G.J.; Ibba, M.; Söll, D. Aminoacyl-tRNA synthetases, the genetic code, and the evolutionary process. Microbiol. Mol. Biol. Rev., 2000, 64(1), 202-236.
[http://dx.doi.org/10.1128/MMBR.64.1.202-236.2000] [PMID: 10704480]
[86]
Deniziak, M.A.; Barciszewski, J. Methionyl-tRNA synthetase. Acta Biochim. Pol., 2001, 48(2), 337-350.
[http://dx.doi.org/10.18388/abp.2001_3919] [PMID: 11732605]
[87]
Ojo, K.K.; Ranade, R.M.; Zhang, Z.; Dranow, D.M.; Myers, J.B.; Choi, R.; Nakazawa Hewitt, S.; Edwards, T.E.; Davies, D.R.; Lorimer, D.; Boyle, S.M.; Barrett, L.K.; Buckner, F.S.; Fan, E.; Van Voorhis, W.C. Brucella melitensis Methionyl-tRNA-Synthetase (MetRS), a potential drug target for Brucellosis. PLoS One, 2016, 11(8), e0160350.
[http://dx.doi.org/10.1371/journal.pone.0160350] [PMID: 27500735]
[88]
Shibata, S.; Gillespie, J.R.; Kelley, A.M.; Napuli, A.J.; Zhang, Z.; Kovzun, K.V.; Pefley, R.M.; Lam, J.; Zucker, F.H.; Van Voorhis, W.C.; Merritt, E.A.; Hol, W.G.J.; Verlinde, C.L.M.J.; Fan, E.; Buckner, F.S. Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei infection in mice. Antimicrob. Agents Chemother., 2011, 55(5), 1982-1989.
[http://dx.doi.org/10.1128/AAC.01796-10] [PMID: 21282428]
[89]
Shibata, S.; Gillespie, J.R.; Ranade, R.M.; Koh, C.Y.; Kim, J.E.; Laydbak, J.U.; Zucker, F.H.; Hol, W.G.J.; Verlinde, C.L.M.J.; Buckner, F.S.; Fan, E. Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: Selectivity and in vivo characterization. J. Med. Chem., 2012, 55(14), 6342-6351.
[http://dx.doi.org/10.1021/jm300303e] [PMID: 22720744]
[90]
Regan, J.; Capolino, A.; Cirillo, P.F.; Gilmore, T.; Graham, A.G.; Hickey, E.; Kroe, R.R.; Madwed, J.; Moriak, M.; Nelson, R.; Pargellis, C.A.; Swinamer, A.; Torcellini, C.; Tsang, M.; Moss, N. Structure−activity relationships of the p38α MAP kinase inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph-thalen-1-yl]urea (BIRB 796). J. Med. Chem., 2003, 46(22), 4676-4686.
[http://dx.doi.org/10.1021/jm030121k] [PMID: 14561087]
[91]
Rowaiye, A.B.; Ogugua, A.J.; Ibeanu, G.; Bur, D.; Asala, M.T.; Ogbeide, O.B.; Abraham, E.O.; Usman, H.B. Identifying potential natural inhibitors of Brucella melitensis Methionyl-tRNA synthetase through an in-silico approach. PLoS Negl. Trop. Dis., 2022, 16(3), e0009799.
[http://dx.doi.org/10.1371/journal.pntd.0009799] [PMID: 35312681]
[92]
Kumari, M.; chandra, S.; Tiwari, N.; Subbarao, N. High throughput virtual screening to identify novel natural product inhibitors for MethionyltRNA-Synthetase of Brucella melitensis. Bioinformation, 2017, 13(1), 8-16.
[http://dx.doi.org/10.6026/97320630013008] [PMID: 28479744]
[93]
Li, M.; Wen, F.; Zhao, S.; Wang, P.; Li, S.; Zhang, Y.; Zheng, N.; Wang, J. Exploring the molecular basis for binding of inhibitors by Threonyl-tRNA synthetase from Brucella abortus: A virtual screening study. Int. J. Mol. Sci., 2016, 17(7), 1078.
[http://dx.doi.org/10.3390/ijms17071078] [PMID: 27447614]
[94]
Powers, H.J. Riboflavin (vitamin B-2) and health. Am. J. Clin. Nutr., 2003, 77(6), 1352-1360.
[http://dx.doi.org/10.1093/ajcn/77.6.1352] [PMID: 12791609]
[95]
Walsh, C.T.; Wencewicz, T.A. Flavoenzymes: Versatile catalysts in biosynthetic pathways. Nat. Prod. Rep., 2013, 30(1), 175-200.
[http://dx.doi.org/10.1039/C2NP20069D] [PMID: 23051833]
[96]
Leys, D.; Scrutton, N.S. Sweating the assets of flavin cofactors: New insight of chemical versatility from knowledge of structure and mechanism. Curr. Opin. Struct. Biol., 2016, 41, 19-26.
[http://dx.doi.org/10.1016/j.sbi.2016.05.014] [PMID: 27266331]
[97]
Long, Q.; Ji, L.; Wang, H.; Xie, J. Riboflavin biosynthetic and regulatory factors as potential novel anti-infective drug targets. Chem. Biol. Drug Des., 2010, 75(4), 339-347.
[http://dx.doi.org/10.1111/j.1747-0285.2010.00946.x] [PMID: 20148904]
[98]
Moreno, A.; Taleb, V.; Sebastián, M.; Anoz-Carbonell, E.; Martínez-Júlvez, M.; Medina, M. Cofactors and pathogens: Flavin mononucleotide and flavin adenine dinucleotide (FAD) biosynthesis by the FAD synthase from Brucella ovis. IUBMB Life, 2022, 74(7), 655-671.
[http://dx.doi.org/10.1002/iub.2576] [PMID: 34813144]
[99]
Cushman, M.; Jin, G.; Illarionov, B.; Fischer, M.; Ladenstein, R.; Bacher, A.; Bacher, A. Design, synthesis, and biochemical evaluation of 1,5,6,7-tetrahydro-6,7-dioxo-9-D-ribitylaminolumazines bearing alkyl phosphate substituents as inhibitors of lumazine synthase and riboflavin synthase. J. Org. Chem., 2005, 70(20), 8162-8170.
[http://dx.doi.org/10.1021/jo051332v] [PMID: 16277343]
[100]
Zhang, Y.; Illarionov, B.; Morgunova, E.; Jin, G.; Bacher, A.; Fischer, M.; Ladenstein, R.; Cushman, M. A new series of N-[2,4-dioxo-6-d-ribitylamino-1,2,3,4-tetrahydropyrimi-din-5-yl]oxalamic acid derivatives as inhibitors of lumazine synthase and riboflavin synthase: design, synthesis, biochemical evaluation, crystallography, and mechanistic implications. J. Org. Chem., 2008, 73(7), 2715-2724.
[http://dx.doi.org/10.1021/jo702631a] [PMID: 18331058]
[101]
Serer, M.I.; Bonomi, H.R.; Guimarães, B.G.; Rossi, R.C.; Goldbaum, F.A.; Klinke, S. Crystallographic and kinetic study of riboflavin synthase from Brucella abortus, a chemotherapeutic target with an enhanced intrinsic flexibility. Acta Crystallogr. D Biol. Crystallogr., 2014, 70(5), 1419-1434.
[http://dx.doi.org/10.1107/S1399004714005161] [PMID: 24816110]
[102]
Serer, M.I.; Carrica, M.C.; Trappe, J.; López Romero, S.; Bonomi, H.R.; Klinke, S.; Cerutti, M.L.; Goldbaum, F.A. A high‐throughput screening for inhibitors of riboflavin synthase identifies novel antimicrobial compounds to treat brucellosis. FEBS J., 2019, 286(13), 2522-2535.
[http://dx.doi.org/10.1111/febs.14829] [PMID: 30927485]
[103]
Kumar, R.; Bhakuni, V. A functionally active dimer of Mycobacterium tuberculosis malate synthase G. Eur. Biophys. J., 2010, 39(11), 1557-1562.
[http://dx.doi.org/10.1007/s00249-010-0598-7] [PMID: 20306314]
[104]
Adi, P.J.; Yellapu, N.K.; Matcha, B. Modeling, molecular docking, probing catalytic binding mode of acetyl-CoA malate synthase G in Brucella melitensis 16M. Biochem. Biophys. Rep., 2016, 8, 192-199.
[http://dx.doi.org/10.1016/j.bbrep.2016.08.020] [PMID: 28955956]
[105]
Muhammad, I.; Niaz, S.; Hussain, A.; Ahmad, S.; Rahman, N.; Khan, H.; Ali, A. Nayab, Gul E. Molecular docking and in vitro analysis of Fagonia cretica and Berberis lyceum extracts against Brucella melitensis. Curr. Computeraided Drug Des., 2021, 17(7), 946-956.
[http://dx.doi.org/10.2174/1573409916666200612145712] [PMID: 32532195]
[106]
Kamal, I.M.; Chakrabarti, S. MetaDOCK: A combinatorial molecular docking approach. ACS Omega, 2023, 8(6), 5850-5860.
[http://dx.doi.org/10.1021/acsomega.2c07619] [PMID: 36816658]
[107]
Pradeepkiran, J.A.; konidala, K.; Yellapu, N.; Bhaskar, M. Modeling, molecular dynamics, and docking assessment of transcription factor rho: a potential drug target in Brucella melitensis 16M. Drug Des. Devel. Ther., 2015, 9, 1897-1912.
[http://dx.doi.org/10.2147/DDDT.S77020] [PMID: 25848225]
[108]
Kushwaha, S.K.; Shakya, M. Protein interaction network analysis—Approach for potential drug target identification in Mycobacterium tuberculosis. J. Theor. Biol., 2010, 262(2), 284-294.
[http://dx.doi.org/10.1016/j.jtbi.2009.09.029] [PMID: 19833135]
[109]
Gupta, M.; Prasad, Y.; Sharma, S.K.; Jain, C.K. Identification of Phosphoribosyl-AMP cyclohydrolase, as drug target and its inhibitors in Brucella melitensis bv. 1 16M using metabolic pathway analysis. J. Biomol. Struct. Dyn., 2017, 35(2), 287-299.
[http://dx.doi.org/10.1080/07391102.2015.1137229] [PMID: 26725317]
[110]
Mancini, D.T.; Matos, K.S.; da Cunha, E.F.F.; Assis, T.M.; Guimarães, A.P.; França, T.C.C.; Ramalho, T.C. Molecular modeling studies on nucleoside hydrolase from the biological warfare agent Brucella suis. J. Biomol. Struct. Dyn., 2012, 30(1), 125-136.
[http://dx.doi.org/10.1080/07391102.2012.674293] [PMID: 22571438]
[111]
Bie, P.; Yang, X.; Zhang, C.; Wu, Q. Identification of small-molecule inhibitors of Brucella diaminopimelate decarboxylase by using a high-throughput screening assay. Front. Microbiol., 2020, 10, 2936.
[http://dx.doi.org/10.3389/fmicb.2019.02936] [PMID: 32038511]
[112]
Scarff, J.M.; Waidyarachchi, S.L.; Meyer, C.J.; Lane, D.J.; Chai, W.; Lemmon, M.M.; Liu, J.; Butler, M.M.; Bowlin, T.L.; Lee, R.E.; Panchal, R.G. Aminomethyl spectinomycins: A novel antibacterial chemotype for biothreat pathogens. J. Antibiot., 2019, 72(9), 693-701.
[http://dx.doi.org/10.1038/s41429-019-0194-8] [PMID: 31164713]
[113]
Reuter, S.; Gupta, S.C.; Phromnoi, K.; Aggarwal, B.B. Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: A new use for an old drug. Br. J. Pharmacol., 2012, 165(7), 2127-2139.
[http://dx.doi.org/10.1111/j.1476-5381.2011.01702.x] [PMID: 21955206]
[114]
Gross, A.; Terraza, A.; Marchant, J.; Bouaboula, M.; Ouahrani-Bettache, S.; Liautard, J.P.; Casellas, P.; Dornand, J. A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis. J. Leukoc. Biol., 2000, 67(3), 335-344.
[http://dx.doi.org/10.1002/jlb.67.3.335] [PMID: 10733093]
[115]
Boigegrain, R.A.; Liautard, J.P.; Köhler, S. Targeting of the virulence factor acetohydroxyacid synthase by sulfonylureas results in inhibition of intramacrophagic multiplication of Brucella suis. Antimicrob. Agents Chemother., 2005, 49(9), 3922-3925.
[http://dx.doi.org/10.1128/AAC.49.9.3922-3925.2005] [PMID: 16127072]
[116]
Kutlu, M.; Ergin, Ç.; Sen-Türk, N.; Sayin-Kutlu, S.; Zorbozan, O.; Akalın, S.; Şahin, B.; Çobankara, V.; Demirkan, N. Acute Brucella melitensis m16 infection model in mice treated with tumor necrosis factor-alpha inhibitors. J. Infect. Dev. Ctries., 2015, 9(2), 141-148.
[http://dx.doi.org/10.3855/jidc.5155] [PMID: 25699488]
[117]
Gagnaire, A.; Gorvel, L.; Papadopoulos, A.; Von Bargen, K.; Mège, J.L.; Gorvel, J.P. COX-2 inhibition reduces Brucella bacterial burden in draining lymph nodes. Front. Microbiol., 2016, 7, 1987.
[http://dx.doi.org/10.3389/fmicb.2016.01987] [PMID: 28018318]
[118]
Czyż, D.M.; Jain-Gupta, N.; Shuman, H.A.; Crosson, S. A dual-targeting approach to inhibit Brucella abortus replication in human cells. Sci. Rep., 2016, 6(1), 35835.
[http://dx.doi.org/10.1038/srep35835] [PMID: 27767061]
[119]
Reyes, A.W.B.; Hop, H.T.; Arayan, L.T.; Huy, T.X.N.; Min, W.; Lee, H.J.; Chang, H.H.; Kim, S. Nocodazole treatment interrupted Brucella abortus invasion in RAW 264.7 cells, and successfully attenuated splenic proliferation with enhanced inflammatory response in mice. Microb. Pathog., 2017, 103, 87-93.
[http://dx.doi.org/10.1016/j.micpath.2016.11.028] [PMID: 28017899]
[120]
Wang, Y.; Li, Y.; Li, H.; Song, H.; Zhai, N.; Lou, L.; Wang, F.; Zhang, K.; Bao, W.; Jin, X.; Su, L.; Tu, Z. Brucella dysregulates monocytes and inhibits macrophage polarization through LC3-Dependent autophagy. Front. Immunol., 2017, 8, 691.
[http://dx.doi.org/10.3389/fimmu.2017.00691] [PMID: 28659924]
[121]
Reyes, A.W.B.; Arayan, L.T.; Huy, T.X.N.; Vu, S.H.; Kang, C.K.; Min, W.; Lee, H.J.; Lee, J.H.; Kim, S. Chemokine receptor 4 (CXCR4) blockade enhances resistance to bacterial internalization in RAW264.7 cells and AMD3100, a CXCR4 antagonist, attenuates susceptibility to Brucella abortus 544 infection in a murine model. Vet. Microbiol., 2019, 237, 108402.
[http://dx.doi.org/10.1016/j.vetmic.2019.108402] [PMID: 31585647]
[122]
Nguyen, T.T.; Kim, H.; Huy, T.X.N.; Min, W.; Lee, H.; Reyes, A.W.B.; Lee, J.; Kim, S. Simvastatin inhibits Brucella abortus invasion into RAW 264.7 cells through suppression of the mevalonate pathway and promotes host immunity during infection in a mouse model. Int. J. Mol. Sci., 2022, 23(15), 8337.
[http://dx.doi.org/10.3390/ijms23158337] [PMID: 35955474]
[123]
Reyes, A.W.B.; Kim, H.; Huy, T.X.N.; Nguyen, T.T.; Min, W.; Lee, D.; Hur, J.; Lee, J.H.; Kim, S. The in vitro and in vivo effect of lipoxygenase pathway inhibitors nordihydroguaiaretic acid and its derivative tetra-O-methyl Nordihydroguaiaretic acid against Brucella abortus 544. J. Microbiol. Biotechnol., 2022, 32(9), 1126-1133.
[http://dx.doi.org/10.4014/jmb.2207.07026] [PMID: 36039381]
[124]
Reyes, A.W.B.; Vu, S.H.; Huy, T.X.N.; Min, W.; Lee, H.J.; Chang, H.H.; Lee, J.H.; Kim, S. Adenosine receptor Adora2b antagonism attenuates Brucella abortus 544 infection in professional phagocyte RAW 264.7 cells and BALB/c mice. Vet. Microbiol., 2020, 242, 108586.
[http://dx.doi.org/10.1016/j.vetmic.2020.108586] [PMID: 32122590]
[125]
Reyes, A.W.B.; Huy, T.X.N.; Vu, S.H.; Kang, C.K.; Min, W.; Lee, H.J.; Lee, J.H.; Kim, S. Formyl peptide receptor 2 (FPR2) antagonism is a potential target for the prevention of Brucella abortus 544 infection. Immunobiology, 2021, 226(3), 152073.
[http://dx.doi.org/10.1016/j.imbio.2021.152073] [PMID: 33657463]
[126]
Wang, L.L.; Chen, X.F.; Hu, P.; Lu, S.Y.; Fu, B.Q.; Li, Y.S.; Zhai, F.F.; Ju, D.D.; Zhang, S.J.; Shui, Y.M.; Chang, J.; Ma, X.L.; Su, B.; Zhou, Y.; Liu, Z.S.; Ren, H.L. Host Prdx6 contributing to the intracellular survival of Brucella suis S2 strain. BMC Vet. Res., 2019, 15(1), 304.
[http://dx.doi.org/10.1186/s12917-019-2049-8] [PMID: 31438945]

Rights & Permissions Print Cite
Article Metrics
33
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy